613 related articles for article (PubMed ID: 28739932)
1. CDCP1 drives triple-negative breast cancer metastasis through reduction of lipid-droplet abundance and stimulation of fatty acid oxidation.
Wright HJ; Hou J; Xu B; Cortez M; Potma EO; Tromberg BJ; Razorenova OV
Proc Natl Acad Sci U S A; 2017 Aug; 114(32):E6556-E6565. PubMed ID: 28739932
[TBL] [Abstract][Full Text] [Related]
2. CDCP1 cleavage is necessary for homodimerization-induced migration of triple-negative breast cancer.
Wright HJ; Arulmoli J; Motazedi M; Nelson LJ; Heinemann FS; Flanagan LA; Razorenova OV
Oncogene; 2016 Sep; 35(36):4762-72. PubMed ID: 26876198
[TBL] [Abstract][Full Text] [Related]
3. FBXL14 abolishes breast cancer progression by targeting CDCP1 for proteasomal degradation.
Cui YH; Kim H; Lee M; Yi JM; Kim RK; Uddin N; Yoo KC; Kang JH; Choi MY; Cha HJ; Kwon OS; Bae IH; Kim MJ; Kaushik N; Lee SJ
Oncogene; 2018 Oct; 37(43):5794-5809. PubMed ID: 29973690
[TBL] [Abstract][Full Text] [Related]
4. The PDGFRβ/ERK1/2 pathway regulates CDCP1 expression in triple-negative breast cancer.
Forte L; Turdo F; Ghirelli C; Aiello P; Casalini P; Iorio MV; D'Ippolito E; Gasparini P; Agresti R; Belmonte B; Sozzi G; Sfondrini L; Tagliabue E; Campiglio M; Bianchi F
BMC Cancer; 2018 May; 18(1):586. PubMed ID: 29792166
[TBL] [Abstract][Full Text] [Related]
5. CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers.
Turdo F; Bianchi F; Gasparini P; Sandri M; Sasso M; De Cecco L; Forte L; Casalini P; Aiello P; Sfondrini L; Agresti R; Carcangiu ML; Plantamura I; Sozzi G; Tagliabue E; Campiglio M
Oncotarget; 2016 Oct; 7(43):69649-69665. PubMed ID: 27626701
[TBL] [Abstract][Full Text] [Related]
6. CUB domain-containing protein 1, a prognostic factor for human pancreatic cancers, promotes cell migration and extracellular matrix degradation.
Miyazawa Y; Uekita T; Hiraoka N; Fujii S; Kosuge T; Kanai Y; Nojima Y; Sakai R
Cancer Res; 2010 Jun; 70(12):5136-46. PubMed ID: 20501830
[TBL] [Abstract][Full Text] [Related]
7. Nitro-fatty acid inhibition of triple-negative breast cancer cell viability, migration, invasion, and tumor growth.
Woodcock CC; Huang Y; Woodcock SR; Salvatore SR; Singh B; Golin-Bisello F; Davidson NE; Neumann CA; Freeman BA; Wendell SG
J Biol Chem; 2018 Jan; 293(4):1120-1137. PubMed ID: 29158255
[TBL] [Abstract][Full Text] [Related]
8. ADAM9 enhances CDCP1 by inhibiting miR-1 through EGFR signaling activation in lung cancer metastasis.
Chiu KL; Lin YS; Kuo TT; Lo CC; Huang YK; Chang HF; Chuang EY; Lin CC; Cheng WC; Liu YN; Lai LC; Sher YP
Oncotarget; 2017 Jul; 8(29):47365-47378. PubMed ID: 28537886
[TBL] [Abstract][Full Text] [Related]
9. Regulation of inside-out β1-integrin activation by CDCP1.
Pollan SG; Huang F; Sperger JM; Lang JM; Morrissey C; Cress AE; Chu CY; Bhowmick NA; You S; Freeman MR; Spassov DS; Moasser MM; Carter WG; Satapathy SR; Shah K; Knudsen BS
Oncogene; 2018 May; 37(21):2817-2836. PubMed ID: 29511352
[TBL] [Abstract][Full Text] [Related]
10. CUB-domain-containing protein 1 (CDCP1) activates Src to promote melanoma metastasis.
Liu H; Ong SE; Badu-Nkansah K; Schindler J; White FM; Hynes RO
Proc Natl Acad Sci U S A; 2011 Jan; 108(4):1379-84. PubMed ID: 21220330
[TBL] [Abstract][Full Text] [Related]
11. HRD1 inhibits fatty acid oxidation and tumorigenesis by ubiquitinating CPT2 in triple-negative breast cancer.
Guo X; Wang A; Wang W; Wang Y; Chen H; Liu X; Xia T; Zhang A; Chen D; Qi H; Ling T; Piao HL; Wang HJ
Mol Oncol; 2021 Feb; 15(2):642-656. PubMed ID: 33207079
[TBL] [Abstract][Full Text] [Related]
12. Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer.
Harrington BS; He Y; Davies CM; Wallace SJ; Adams MN; Beaven EA; Roche DK; Kennedy C; Chetty NP; Crandon AJ; Flatley C; Oliveira NB; Shannon CM; deFazio A; Tinker AV; Gilks CB; Gabrielli B; Brennan DJ; Coward JI; Armes JE; Perrin LC; Hooper JD
Br J Cancer; 2016 Feb; 114(4):417-26. PubMed ID: 26882065
[TBL] [Abstract][Full Text] [Related]
13. ACSL4-Mediated Membrane Phospholipid Remodeling Induces Integrin β1 Activation to Facilitate Triple-Negative Breast Cancer Metastasis.
Qiu Y; Wang X; Sun Y; Jin T; Tang R; Zhou X; Xu M; Gan Y; Wang R; Luo H; Liu M; Tang X
Cancer Res; 2024 Jun; 84(11):1856-1871. PubMed ID: 38471082
[TBL] [Abstract][Full Text] [Related]
14. Myoferlin regulates cellular lipid metabolism and promotes metastases in triple-negative breast cancer.
Blomme A; Costanza B; de Tullio P; Thiry M; Van Simaeys G; Boutry S; Doumont G; Di Valentin E; Hirano T; Yokobori T; Gofflot S; Peulen O; Bellahcène A; Sherer F; Le Goff C; Cavalier E; Mouithys-Mickalad A; Jouret F; Cusumano PG; Lifrange E; Muller RN; Goldman S; Delvenne P; De Pauw E; Nishiyama M; Castronovo V; Turtoi A
Oncogene; 2017 Apr; 36(15):2116-2130. PubMed ID: 27775075
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic Ras/ERK signaling activates CDCP1 to promote tumor invasion and metastasis.
Uekita T; Fujii S; Miyazawa Y; Iwakawa R; Narisawa-Saito M; Nakashima K; Tsuta K; Tsuda H; Kiyono T; Yokota J; Sakai R
Mol Cancer Res; 2014 Oct; 12(10):1449-59. PubMed ID: 24939643
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer.
Camarda R; Zhou AY; Kohnz RA; Balakrishnan S; Mahieu C; Anderton B; Eyob H; Kajimura S; Tward A; Krings G; Nomura DK; Goga A
Nat Med; 2016 Apr; 22(4):427-32. PubMed ID: 26950360
[TBL] [Abstract][Full Text] [Related]
17. AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer.
Chen B; Wang J; Dai D; Zhou Q; Guo X; Tian Z; Huang X; Yang L; Tang H; Xie X
J Exp Clin Cancer Res; 2017 May; 36(1):65. PubMed ID: 28494797
[TBL] [Abstract][Full Text] [Related]
18. ADAM9 enhances CDCP1 protein expression by suppressing miR-218 for lung tumor metastasis.
Chiu KL; Kuo TT; Kuok QY; Lin YS; Hua CH; Lin CY; Su PY; Lai LC; Sher YP
Sci Rep; 2015 Nov; 5():16426. PubMed ID: 26553452
[TBL] [Abstract][Full Text] [Related]
19. Suppression of autophagy by CUB domain-containing protein 1 signaling is essential for anchorage-independent survival of lung cancer cells.
Uekita T; Fujii S; Miyazawa Y; Hashiguchi A; Abe H; Sakamoto M; Sakai R
Cancer Sci; 2013 Jul; 104(7):865-70. PubMed ID: 23510015
[TBL] [Abstract][Full Text] [Related]
20. Fatty acid binding protein 5 promotes metastatic potential of triple negative breast cancer cells through enhancing epidermal growth factor receptor stability.
Powell CA; Nasser MW; Zhao H; Wochna JC; Zhang X; Shapiro C; Shilo K; Ganju RK
Oncotarget; 2015 Mar; 6(8):6373-85. PubMed ID: 25779666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
